foravirumab
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2008 (NCT00656097)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- GlycoproteinINHIBITOR
G inhibitor
- Lyssavirus rabiesImmunity, passive
Lyssavirus rabies immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109564 ↗
- ChEMBLCHEMBL1743021 ↗
Also known as
- cl184
- cl-184
- cr-4098
- foravirumab
- mix of cr-57 and cr-4098
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00708084 | Phase 2 | May 1, 2008 | Crucell, Research Institute for Tropical Medicine, Alabang, Muntinlupa, Metro Manila, Philippines |
| NCT00656097 | Phase 2 | Mar 1, 2008 | Crucell, MDS Pharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Crucell | For profit | 2 | 2 | 1 | 2008 |
| MDS Pharma | For profit | 1 | 0 | 1 | 2008 |
| Research Institute for Tropical Medicine, Alabang, Muntinlupa, Metro Manila, Philippines | Academic/Hospital | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1